OT-A201

Phase 1Small molecule

OOnward Therapeutics

OT-A201 is one of 33 small molecule programs targeting Hematological Malignancies. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hematological MalignanciesRecruiting

Hematological MalignanciesPhase 1

Recruiting

Competition

Competitive Landscape

44 competitors in Hematological Malignancies

#DrugCompanyPhaseTrials

Cytoxan

BBaxter Healthcare Corporation

Phase 3

12 2

Alkeran

AApotex Inc.

Phase 3

2 3

Fludara

Sanofi

Phase 2

10 4

Venclexta

AbbVie

Phase 2

9 5

Cellcept

Roche

Phase 2

5 6

Neoral

Novartis

Phase 2

5 7

Cytosar

Teva

Phase 2

4 8

Fludara

Sanofi

Phase 2

3 9

Jakafi

Incyte

Phase 2

3 10

TALVEY

Johnson & Johnson

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Recruiting

Hematological Malignancies

NCT05828459

Clinical

Trials by Indication[1]

Hematological Malignancies1 trial

First-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors

Recruiting·OOnward Therapeutics·Phase 1·NCT05828459·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for OT-A201. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — OT-A201 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for OT-A201. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Onward Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: OOnward Therapeutics

OT-A201

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Hematological Malignancies1 trial

References

Drug Info

Quick Facts

Related News